Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19.
作者信息
Vuorio Alpo, Raal Frederick, Klingel Reinhard, Kovanen Petri T
机构信息
Mehiläinen Airport Health Centre, Vantaa, Finland; Department of Forensic Medicine, University of Helsinki, Helsinki, Finland.
Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
出版信息
J Clin Lipidol. 2021 Mar-Apr;15(2):379-380. doi: 10.1016/j.jacl.2021.02.002.
Abstract
摘要
相似文献
1
Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19.为何持续脂蛋白分离术对患有COVID-19的纯合子家族性高胆固醇血症患者至关重要。
J Clin Lipidol. 2021 Mar-Apr;15(2):379-380. doi: 10.1016/j.jacl.2021.02.002.
2
Negative impact of COVID-19 pandemic on the lifestyle and management of patients with homozygous familial hypercholesterolemia.COVID-19 大流行对纯合子家族性高胆固醇血症患者生活方式和管理的负面影响。
J Clin Lipidol. 2020 Nov-Dec;14(6):751-755. doi: 10.1016/j.jacl.2020.09.002. Epub 2020 Sep 15.
3
Collateral damage of the COVID-19 pandemic on the management of homozygous familial hypercholesterolemia.新冠疫情对纯合子家族性高胆固醇血症管理造成的附带损害。
J Clin Lipidol. 2021 Mar-Apr;15(2):381-382. doi: 10.1016/j.jacl.2021.02.003.
4
Long-term efficacy of lipoprotein apheresis in homozygous familial hypercholesterolaemia.
Nephrol Dial Transplant. 2000 May;15(5):738-40.
5
Low-density lipoprotein apheresis in homozygous familial hypercholesterolemia.纯合子家族性高胆固醇血症的低密度脂蛋白单采术
Am J Cardiol. 2001 Jul 15;88(2):202-3. doi: 10.1016/s0002-9149(01)01664-2.
6
Role of LDL apheresis in a case of homozygous familial hypercholesterolemia.低密度脂蛋白去除术在一例纯合子家族性高胆固醇血症患者中的作用。
Drug Discov Ther. 2019;13(1):59-61. doi: 10.5582/ddt.2019.01001.
7
[The apheresis of low-density lipoproteins in homozygous familial hypercholesterolemia].[纯合子家族性高胆固醇血症中低密度脂蛋白的单采]
Med Clin (Barc). 1993 Jan 23;100(3):117-8.
8
Pregnancy in a patient with homozygous familial hypercholesterolemia treated with long-term low-density lipoprotein apheresis.长期接受低密度脂蛋白分离术治疗的纯合子家族性高胆固醇血症患者的妊娠情况。
Metabolism. 1994 Sep;43(9):1164-70. doi: 10.1016/0026-0495(94)90061-2.
9
Comment on "Homozygous familial hypercholesterolemia with severe involvement of the aortic valve: A sibling-controlled case study on the efficacy of lipoprotein apheresis".关于“主动脉瓣严重受累的纯合子家族性高胆固醇血症：脂蛋白分离术疗效的同胞对照病例研究”的评论
J Clin Apher. 2021 Feb;36(1):219-220. doi: 10.1002/jca.21834. Epub 2020 Oct 1.
10
Current Role of Lipoprotein Apheresis.脂蛋白吸附术的当前作用。
Curr Atheroscler Rep. 2019 May 1;21(7):26. doi: 10.1007/s11883-019-0787-5.
引用本文的文献
1
Familial Hypercholesterolemia Patients with COVID-19-Effective Cholesterol-Lowering Therapy is Urgent both during and after Infection.家族性高胆固醇血症合并新型冠状病毒肺炎患者——感染期间及感染后均急需有效的降胆固醇治疗
Rev Cardiovasc Med. 2022 Dec 19;23(12):410. doi: 10.31083/j.rcm2312410. eCollection 2022 Dec.
2
Low-density lipoprotein apheresis is associated with removal of SARS-CoV-2 antibodies.低密度脂蛋白吸附术与 SARS-CoV-2 抗体的清除有关。
Ther Apher Dial. 2022 Dec;26(6):1289-1295. doi: 10.1111/1744-9987.13842. Epub 2022 Apr 7.
3
Collateral damage of the COVID-19 pandemic on the management of homozygous familial hypercholesterolemia.新冠疫情对纯合子家族性高胆固醇血症管理造成的附带损害。
J Clin Lipidol. 2021 Mar-Apr;15(2):381-382. doi: 10.1016/j.jacl.2021.02.003.
本文引用的文献
1
PCSK9 inhibitors for COVID-19: an opportunity to enhance the antiviral action of interferon in patients with hypercholesterolaemia.用于治疗新冠肺炎的前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂：提高高胆固醇血症患者干扰素抗病毒作用的契机
J Intern Med. 2021 May;289(5):749-751. doi: 10.1111/joim.13210. Epub 2020 Dec 19.
2
Negative impact of COVID-19 pandemic on the lifestyle and management of patients with homozygous familial hypercholesterolemia.COVID-19 大流行对纯合子家族性高胆固醇血症患者生活方式和管理的负面影响。
J Clin Lipidol. 2020 Nov-Dec;14(6):751-755. doi: 10.1016/j.jacl.2020.09.002. Epub 2020 Sep 15.
3
Cardiovascular Outcome of Pediatric Patients With Bi-Allelic (Homozygous) Familial Hypercholesterolemia Before and After Initiation of Multimodal Lipid Lowering Therapy Including Lipoprotein Apheresis.多模式降脂治疗（包括脂蛋白吸附）对双等位基因（纯合子）家族性高胆固醇血症儿科患者心血管结局的影响。
Am J Cardiol. 2020 Dec 1;136:38-48. doi: 10.1016/j.amjcard.2020.09.015. Epub 2020 Sep 16.
4
COVID-19 is, in the end, an endothelial disease.COVID-19 归根结底是一种血管内皮疾病。
Eur Heart J. 2020 Sep 1;41(32):3038-3044. doi: 10.1093/eurheartj/ehaa623.
5
Incidence of venous and arterial thromboembolic complications in COVID-19: A systematic review and meta-analysis.新型冠状病毒肺炎患者静脉和动脉血栓栓塞并发症的发生率：一项系统评价和荟萃分析。
Thromb Res. 2020 Dec;196:27-30. doi: 10.1016/j.thromres.2020.08.022. Epub 2020 Aug 11.
6
Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia.预防家族性高胆固醇血症的新冠肺炎患者出现内皮功能障碍和血栓形成事件。
J Clin Lipidol. 2020 Sep-Oct;14(5):617-618. doi: 10.1016/j.jacl.2020.06.006. Epub 2020 Jun 15.
7
Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic.关于 COVID-19 大流行期间家族性高胆固醇血症成年患者管理的简要建议。
Pharmacol Res. 2020 Aug;158:104891. doi: 10.1016/j.phrs.2020.104891. Epub 2020 May 7.
8
Familial hypercholesterolaemia and COVID-19: triggering of increased sustained cardiovascular risk.家族性高胆固醇血症与2019冠状病毒病：引发持续升高的心血管风险
J Intern Med. 2020 Jun;287(6):746-747. doi: 10.1111/joim.13070. Epub 2020 Apr 22.
9
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia.长期依洛尤单抗治疗家族性高胆固醇血症患者的疗效。
J Am Coll Cardiol. 2020 Feb 18;75(6):565-574. doi: 10.1016/j.jacc.2019.12.020.
10
Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.家族性高胆固醇血症和脂蛋白(a)升高：双重遗传性风险和新的治疗机会。
J Intern Med. 2020 Jan;287(1):2-18. doi: 10.1111/joim.12981.
Zotero 插件